{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:45Z","timestamp":1790742045581,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372611"],"award-info":[{"award-number":["82372611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["21MC1930200"],"award-info":[{"award-number":["21MC1930200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115963","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T02:28:49Z","timestamp":1765420129000},"page":"115963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["ELK3-SERPINE1-PCBP2 axis promotes gefitinib resistance in lung cancer by inhibiting ferroptosis"],"prefix":"10.1016","volume":"169","author":[{"given":"Xunxia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jionglin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10299","key":"10.1016\/j.intimp.2025.115963_bb0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2025.115963_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1110207","article-title":"Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy","volume":"13","author":"Jia","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2025.115963_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies","volume":"170","author":"Johnson","year":"2022","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2025.115963_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188967","article-title":"20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2025.115963_bb0025","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3390\/pharmaceutics15061604","article-title":"The resistance to EGFR-TKIs in non-small cell lung Cancer: from molecular mechanisms to clinical application of new therapeutic strategies","volume":"15","author":"Laface","year":"2023","journal-title":"Pharmaceutics"},{"issue":"18","key":"10.1016\/j.intimp.2025.115963_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251810008","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors in Cancer: current use and future prospects","volume":"25","author":"Dickerson","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2025.115963_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40291-021-00568-w","article-title":"MET-targeted therapies and clinical outcomes: a systematic literature review","volume":"26","author":"Dong","year":"2022","journal-title":"Mol. Diagn. Ther."},{"issue":"19","key":"10.1016\/j.intimp.2025.115963_bb0040","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/cancers13194926","article-title":"Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring","volume":"13","author":"Reita","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115963_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216117","article-title":"Good or bad: paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.intimp.2025.115963_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0042-1758791","article-title":"Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1)","volume":"49","author":"Morrow","year":"2023","journal-title":"Semin. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.intimp.2025.115963_bb0055","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/cas.70050","article-title":"Permeable lung vasculature creates Chemoresistant endothelial niche by producing SERPINE1 at breast Cancer metastatic sites","volume":"116","author":"Hongu","year":"2025","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0060","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-024-01985-1","article-title":"Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-kappaB p65 nuclear translocation","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-024-03269-4","article-title":"Gastric cancer-derived exosomal let-7 g-5p mediated by SERPINE1 promotes macrophage M2 polarization and gastric cancer progression","volume":"44","author":"Ye","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.115963_bb0070","first-page":"1875","article-title":"Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA","volume":"44","author":"Zhang","year":"2020","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41419-025-07855-y","article-title":"Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype","volume":"16","author":"Wong","year":"2025","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.intimp.2025.115963_bb0080","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i5.104522","article-title":"Simvastatin inhibits proliferation and migration, promotes oxidative stress and ferroptosis in colon cancer","volume":"17","author":"Liu","year":"2025","journal-title":"World J Gastrointest Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115963_bb0090","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115963_bb0095","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41418-020-00728-1","article-title":"Cellular degradation systems in ferroptosis","volume":"28","author":"Chen","year":"2021","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41420-022-01218-8","article-title":"Role of ferroptosis on tumor progression and immunotherapy","volume":"8","author":"Gong","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2025.115963_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2022.104777","article-title":"Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p\/miR-615-3p axis","volume":"274","author":"Han","year":"2023","journal-title":"J. Proteomics"},{"key":"10.1016\/j.intimp.2025.115963_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.927118","article-title":"Targeting of the lipid metabolism impairs resistance to BRAF kinase inhibitor in melanoma","volume":"10","author":"Vergani","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115963_bb0115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/pin.13209","article-title":"PCBP2 knockdown promotes ferroptosis in malignant mesothelioma","volume":"72","author":"Yue","year":"2022","journal-title":"Pathol. Int."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2025.115963_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154728","article-title":"ETS transcription factor ELK3 in human cancers: An emerging therapeutic target","volume":"248","author":"Al-Hawary","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"8","key":"10.1016\/j.intimp.2025.115963_bb0130","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/carcin\/bgp129","article-title":"Increased PEA3\/E1AF and decreased net\/Elk-3, both ETS proteins, characterize human NSCLC progression and regulate caveolin-1 transcription in Calu-1 and NCI-H23 NSCLC cell lines","volume":"30","author":"Sloan","year":"2009","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0135","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1186\/s12885-023-11069-w","article-title":"Glioma angiogenesis is boosted by ELK3 activating the HIF-1 alpha \/VEGF-A signaling axis","volume":"23","author":"Yueyang","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115963_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3892\/ijo.2021.5173","article-title":"Inhibition of the invasion and metastasis of mammary carcinoma cells by NBD peptide targeting S100A4 via the suppression of the Sp1\/MMP-14 axis","volume":"58","author":"Takenaga","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2025.115963_bb0145","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3389\/fphar.2018.01312","article-title":"ABCC10 plays a significant role in the transport of gefitinib and contributes to acquired resistance to gefitinib in NSCLC","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12943-023-01780-4","article-title":"Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2\/YBX1\/QSOX1 axis in EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1479-7364-7-22","article-title":"Update of the human and mouse SERPIN gene superfamily","volume":"7","author":"Heit","year":"2013","journal-title":"Hum. Genomics"},{"issue":"5","key":"10.1016\/j.intimp.2025.115963_bb0160","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung Cancer-epidemiology, pathogenesis, treatment and molecular aspect (review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2025.115963_bb0165","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0170","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.intimp.2025.115963_bb0175","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-22-3059","article-title":"Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung Cancer","volume":"83","author":"Lin","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: a novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0185","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2223377","article-title":"LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2\/NAMPT axis","volume":"24","author":"Chen","year":"2023","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0190","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s40001-025-02787-x","article-title":"GDF-15 upregulates the SLC7A11\/GPX4 signaling axis and promotes mitoxantrone resistance in AML cells","volume":"30","author":"Lu","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115963_bb0195","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/1878-0261.12911","article-title":"LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer","volume":"15","author":"Teng","year":"2021","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3892\/ijo.2020.5153","article-title":"Crosstalk between YAP and TGFbeta regulates SERPINE1 expression in mesenchymal lung cancer cells","volume":"58","author":"Kong","year":"2021","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115963_bb0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/CBM-220222","article-title":"Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response","volume":"39","author":"Setiawan","year":"2024","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.intimp.2025.115963_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111763","article-title":"Engineered nanovesicles targeting SERPINE1 overcome temozolomide resistance in glioblastoma","volume":"132","author":"Wen","year":"2025","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.intimp.2025.115963_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300644","article-title":"PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer","volume":"19","author":"Thu","year":"2024","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.intimp.2025.115963_bb0220","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/cancers15041092","article-title":"Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition","volume":"15","author":"Tokumo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.32604\/or.2023.042945","article-title":"ELK3-ID4 axis governs the metastatic features of triple negative breast cancer","volume":"32","author":"Choi","year":"2023","journal-title":"Oncol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115963_bb0230","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.3390\/ijms23073709","article-title":"ELK3 controls gastric Cancer cell migration and invasion by regulating ECM Remodeling-related genes","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115963_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1604859","article-title":"Regulation of RHBDD1 in the invasion of esophageal cancer cells via ELK3\/Wnt\/beta-catenin signaling pathway","volume":"13","author":"Xu","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115963_bb0240","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41419-024-06647-0","article-title":"ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance","volume":"15","author":"Lee","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115963_bb0245","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2406159","article-title":"Silencing of ELK3 induces S-M phase arrest and apoptosis and upregulates SERPINE1 expression reducing migration in prostate Cancer cells","volume":"2020","author":"Mao","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.intimp.2025.115963_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116618","article-title":"Diagnostic and therapeutic value of human serpin family proteins","volume":"175","author":"Janciauskiene","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.intimp.2025.115963_bb0255","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/genes10060460","article-title":"Changes in Serum Iron and Leukocyte mRNA Levels of Genes Involved in Iron Metabolism in Amateur Marathon Runners-Effect of the Running Pace","volume":"10","author":"Grzybkowska","year":"2019","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115963_bb0260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-025-02296-7","article-title":"Acevaltrate as a novel ferroptosis inducer with dual targets of PCBP1\/2 and GPX4 in colorectal cancer","volume":"10","author":"Yu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2025.115963_bb0265","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/1440-1681.13523","article-title":"The circular RNA circ_GRHPR promotes NSCLC cell proliferation and invasion via interactions with the RNA-binding protein PCBP2","volume":"48","author":"Hou","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115963_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103584","article-title":"Driving the degradation of oncofusion proteins for targeted cancer therapy","volume":"28","author":"Zhang","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.intimp.2025.115963_bb0275","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s42977-022-00117-4","article-title":"The role of K63-linked polyubiquitin in several types of autophagy","volume":"73","author":"Dosa","year":"2022","journal-title":"Biol Futur."},{"issue":"7","key":"10.1016\/j.intimp.2025.115963_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133786","article-title":"Small molecule inhibitors of plasminogen activator Inhibitor-1 elicit anti-tumorigenic and anti-angiogenic activity","volume":"10","author":"Placencio","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2025.115963_bb0285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2020.02.015","article-title":"Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs","volume":"483","author":"Su","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2025.115963_bb0290","article-title":"Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies","author":"Chen","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:58:31Z","timestamp":1771520311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925019514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":57,"alternative-id":["S1567576925019514"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115963","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ELK3-SERPINE1-PCBP2 axis promotes gefitinib resistance in lung cancer by inhibiting ferroptosis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115963"}}